George Sledge, Jr., MD, professor of Medicine and chief, Division of Oncology, Stanford University, discusses the benefit to the cost of genomic sequencing decreasing overtime.

With this cost continuously dropping, for the first time oncologists are able to do comprehensive looks at mutations in human patients with cancer. By doing so, they can do a better job at tailoring therapy for those patients.

Videos

George Sledge, Jr., MD, discusses the benefit to the cost of genomic sequencing decreasing overtime.

George Sledge, Jr., MD

Articles

Dr. Sledge on Genomic Sequencing in Patients With Breast Cancer